Agenus | AGEN - Interest Expense On Debt


Agenus reported $14.67M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agenus USD 14.67M 1.35M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 582K 13K Jun/2026
Intrexon USD 2K 5K Jun/2024
J&J USD 43M 25M Mar/2026
Jiangsu Hengrui CNY 254.59M 253.85M Sep/2025
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Merck EUR 137M 33M Jun/2026
Merck USD 525M 46M Jun/2026
Northwest Biotherapeutics USD 1.52M 276K Mar/2024
Novartis USD 462M 119M Jun/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 667M 4M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023